Cedars-Sinai: NEJM - Results From Targeted Therapy for Ulcerative Colitis Study
September 26, 2024
September 26, 2024
LOS ANGELES, California, Sept. 26 (TNSres) -- Cedars-Sinai, a nonprofit academic healthcare organization, issued the following news:
* * *
Phase II Study Shows That Monoclonal Antibody Treatment Developed by Cedars-Sinai Researchers Is Effective for Moderate to Severe Ulcerative Colitis
* * *
An international placebo-controlled study led by Cedars-Sinai suggests that a targeted drug therapy that was developed by researchers at Cedars-Sinai is s . . .
* * *
Phase II Study Shows That Monoclonal Antibody Treatment Developed by Cedars-Sinai Researchers Is Effective for Moderate to Severe Ulcerative Colitis
* * *
An international placebo-controlled study led by Cedars-Sinai suggests that a targeted drug therapy that was developed by researchers at Cedars-Sinai is s . . .